Vanzacaftor/tezacaftor/deutivacaftor
| Combination of | |
|---|---|
| Vanzacaftor | Medication |
| Tezacaftor | Medication |
| Deutivacaftor | CFTR potentiator |
| Clinical data | |
| Trade names | Alyftrek |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
Vanzacaftor/tezacaftor/deutivacaftor, sold under the brand name Alyftrek, is a fixed-dose combination medication used for the treatment of cystic fibrosis.[1] It is a combination of deutivacaftor, a CFTR potentiator; tezacaftor; and vanzacaftor, as the calcium salt, vanzacaftor calcium dihydrate.[1] It is taken by mouth.[1]
The combination was approved for medical use in the United States in December 2024.[2]
Medical uses
[edit]The combination is indicated for the treatment of cystic fibrosis in people aged six years of age and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.[1]
Adverse affects
[edit]The US Food and Drug Administration (FDA) prescription label for the combination contains a boxed warning about drug-induced liver injury and liver failure.[1]
History
[edit]The FDA granted the application for vanzacaftor, tezacaftor, and deutivacaftor combination therapy orphan drug designation.[3]
Society and culture
[edit]Legal status
[edit]The combination was approved for medical use in the United States in December 2024.[2][4]
It is sold under the brand name Alyftrek.[1]
References
[edit]- ^ a b c d e f g https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218730s000lbl.pdf
- ^ a b "Novel Drug Approvals for 2024". U.S. Food and Drug Administration (FDA). 23 December 2024. Retrieved 24 December 2024.
- ^ "Alyftrek Orphan Drug Designations and Approvals". U.S. Food and Drug Administration (FDA). Retrieved 24 December 2024.
- ^ "Vertex Announces US FDA Approval of Alyftrek, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis" (Press release). Vertex. 20 December 2024. Retrieved 24 December 2024 – via Business Wire.
External links
[edit]- Clinical trial number NCT05033080 for "A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)" at ClinicalTrials.gov
- Clinical trial number NCT05076149 for "A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation" at ClinicalTrials.gov
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |